Dallas

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Amyloidosis6 trials
• High blood pressure3 trials
• Metastatic breast cancer2 trials
• Obesity2 trials
• Type 1 diabetes2 trials
• Type 2 diabetes2 trials
• Chronic kidney disease1 trial
• Epilepsy1 trial
• Liver and biliary tract cancer1 trial
• Myasthenia gravis1 trial

Phase

• Phase 38 trials
• Phase 23 trials
• Phase 1/22 trials
• Phase 11 trial
• Phase 41 trial

Status

• Recruiting7 trials
• Active, not recruiting4 trials
• Completed4 trials
• Enrolling by invitation1 trial
• Terminated1 trial

Lead sponsor

• Alnylam Pharmaceuticals13 trials
• Olema Pharmaceuticals, Inc.2 trials
• Alexion Pharmaceuticals, Inc.1 trial
• Jazz Pharmaceuticals1 trial

Running trials

• Recruiting

  TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

  NCT07358078· Alnylam Pharmaceuticals· Source

• Recruiting

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source

  Contact: Olema Pharmaceuticals, Inc.

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

  NCT06845202· Phase 1/2· Alnylam Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

  NCT06600321· Phase 1· Alnylam Pharmaceuticals· Source

• Enrolling by invitation

  A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT06679946· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

  NCT06393712· Phase 2· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

  NCT05044819· Phase 4· Jazz Pharmaceuticals· Source

• Recruiting

  Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

  NCT04202341· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc. (Sponsor)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis4 recruiting
• High blood pressure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myasthenia gravis1 recruiting

Closed trials

• Completed

  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

  NCT06272487· Phase 2· Alnylam Pharmaceuticals· Source

• Terminated

  A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

  NCT05761301· Phase 1/2· Alnylam Pharmaceuticals· Source

• Completed

  Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

  NCT05103332· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

  NCT03997383· Phase 3· Alnylam Pharmaceuticals· Source

• Completed

  HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

  NCT03759379· Phase 3· Alnylam Pharmaceuticals· Source